Corticosteroid receptor function is decreased in depressed patients

Neuroendocrinology

Volumn 65, Issue 3, 1997, Pages 216-222

  Modell, Sieglinde ^a   Yassouridis, Alexander ^a   Huber, Johannes ^a   Holsboer, Florian ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

Author keywords

Adrenal steroid receptors; Adrenal steroids; Clinical neuroendocrinology; Corticotropin releasing hormone; Corticotropins; Depression; Dexamethasone test

Indexed keywords

CORTICOSTEROID RECEPTOR; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; DEXAMETHASONE; HYDROCORTISONE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOTROPIN BLOOD LEVEL; CORTICOTROPIN RELEASE; DEPRESSION; DOSE RESPONSE; FEEDBACK SYSTEM; FEMALE; HORMONE RESPONSE; HUMAN; HUMAN EXPERIMENT; HYDROCORTISONE BLOOD LEVEL; HYDROCORTISONE RELEASE; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MALE; PRIORITY JOURNAL;

ADRENOCORTICOTROPIC HORMONE; ADULT; AGED; CORTICOTROPIN-RELEASING HORMONE; DEPRESSION; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYDROCORTISONE; MALE; MIDDLE AGED; OSMOLAR CONCENTRATION; RECEPTORS, STEROID; REFERENCE VALUES;

EID: 0031027742     PISSN: 00283835     EISSN: 14230194     Source Type: Journal    
DOI: 10.1159/000127275     Document Type: Article

References (44)

1. Ncmcrofî CB, Widcrlov G, Bissettc G, Wallcus H, Karlsson I, Eklund K, Kilts CD, Loosen PT, Vale W: Elevated concentrations of CSF corticotropin-releasing faclor-like immunoreactivi-ty in depressed patients, Science 1984,226: 1342-1344.
2. Owens MJ, Nemeroff CB: Physiology and pharmacology of corticoiropin-rclcasing factor, Pharmacol Rev 1991;43:425-473.
3. Holsboer F, Spengler D, Heuser I: The role of corticotropin-releasing hormone in the pathogenesis of Cushing's disease, anorexia nervosa, alcoholism, affective disorders and dementia, Prog Brain Res 1992;93:385-417.
4. Carroll BJ, Feinberg M, Greden JF, Tarika J, Albala AA, Haskett RF, James N, Kronfol Z, Lohr N, Steiner M, De Vigne JP, Young E: A specific laboratory test for the diagnosis of melancholia, Arch Gen Psychiatry 1981:38: 15-22.
5. Arana GW, Baldessarini RJ, Omsteen M: The dcxamcthasonc suppression test for diagnosis and prognosis in psychiatry, Arch Gen Psychiatry 1991:42:1193-1204.
6. Holsboer F, von Bardeleben U, Wiedemann K, Müller OA, Stalla GK: Serial assessment of corticotropin-releasing hormone response after dcxamethasone in depression: Implications for pathophysiology of DST nonsuppression, Biol Psychiatry 1987;22:228-234.
7. Von Bardelcben U, Holsboer F: Cortisol response to a combined dexamethasone-human corticotropin-relcasing hormone challenge in patients with depression,.1 Neurocndocrinol 1989;1:485-488.
8. Von Bardelcben U, Holsboer F: Effect of age on the cortisol response to human corticotropin-releasing hormone in depressed patients with dexamethasone, Biol Psychiatry 1991;29: 1042-1050.
9. Heuser I, Yassouridis A, Holsboer F: The combined dcxamethasone/CRH test: A refined laboratory test for psychiatric disorders, J Psy-chiatrRes 1994;28:341-356.
10. Holsboer-Trachsler E, Stohler R, Halzinger M: Repealed administration of the combined dexamethasone/hCRH stimulation test during treatment of depression, Psychiatry Res 1991: 38:163-171.
11. I lolsboer-Trachslcr E, Hemmetcr U, Hatzingcr M, Seifritz E, Gerhard U, Hobi V: Sleep deprivation and bright light as potential augmenters of antidcpressant drug treatment-Neurobio-logical and psychometric assessment of course, J PsychiatrRes 1994;28:381-399.
12. Holsboer F, Lauer CJ, Schreiber W, Kricg J-C: Altered hypothalamic-pituitary-adrenocortical regulation in healthy subjects at high familial risk for affective disorders, Ncurocndocrinolo-gv 1995;62:340-347.
13. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 3 rev, Washington, American Psychiatric Association, 1987.
14. Wittchen HU, Zaudig M, Schramm E, Spongier P, Mombur W, KJug J, Horn R: SKJD, Strukturicrtcs Klinisches Interview fur DSM-III-R, Weinhcim, Beltz, 1990.
15. Bock RD: Multivariate Statistical Methods in Behaviour Research, New York, McGraw-Hill, 1975.
16. Shimizu N: Dexamethasone suppression test, Nippon Rinsho 1979:444:2575-2577.
17. Sarai M, Tanigueki N, Kagomolo T, Kamcda H, Kema T, Hishikawa Y: Major depressive episode and low-dose dexamethasone suppression test, Folia Psychiatr Neurol Jpn 1982:36: 109-114.
18. Sarai M, Matsunaga H: Low-dose (0.5 mg) dexamethasone suppression test in depressive patients, Biol Psychiatry 1986;21:744-750.
19. Nuller JC, Ostroumova MN: Resistance to inhibitory effect of dexamethasone in patients with endogenous depression, Acta Psychiatr Scand 1980:61:169-177.
20. Rush JA, Schlesser MA, Giles DE, Crowley GT, Fairchild C, Altshuler KZ: The effect of dosage on the dexamethasone suppression test in normal controls, Psychiatry Res 1982:7; 277-285.
21. Arana GW, Workman RJ, Baldessarini RJ: Association between low plasma levels of dexa-melhasone and elevated levels of cortisol in psychiatric patients given dexamethasone, Am J Psychiatry 1984;141:1619-1620.
22. Holsboer F, Wiedemann K, Gerken A, Boll E: The plasma dexamethasone variable in depression: Test rc-tcst studies and early biophase kinetics, Arch Gen Psychiatry 1986;43:813-815.
23. Wiedemann K, Holsboer F: Plasma dexamethasone levels in depression: Oral vs, intravenous administration, Psvchiatry Res 1986:20:83-85.
24. Wiedemann K, Holsboer F: The effect of dexa-mcthasonc dosage upon plasma cortisol and dexamethasone during DST, J Affect Disord 1990:19:133-137.
25. Gupta SK, Ritchie JC, Ellinwood EH, Wiedemann K, Holsboer F: Modeling the pharmacokinetics and pharmacodynamicsof dexamethasone in depressed patients, Eur J Clin Pharmacol 1992;43:51-55.
26. Dinan TG: Glucocorticoids and the genesis of depressive illness, A psychobiological model, BrJ Psychiatry 1994;164:365-371.
27. Holsboer F, Grasser A, Fricss E, Wiedemann K: Steroid effects on central neurons and implication for psychiatric and neurological disorders, Ann NY Acad Sci 1994;746:345-361.
28. Fink G, Rosie R, Sheward WJ, Thomson E, Wilson H: Steroid control of central neuronal interactions and function, J Steroid Biochem Mol Biol 1991;40:123-132.
29. Von Bardelcben U, Holsboer F, Stalla GK, Müller OA: Combined administration of human corticotropin-releasing factor and vasopressin induces cortisol escape for dexamethasone suppression in healthy subjects, Life Sci 1985;37:1613-1618.
30. Raadshccr FC, Sluiter AA, Ravid R, Tilders FJH, Swaab DF: Localization of corticotropin-releasing hormone neurons in the paraventricular nucleus of the human hypothalamus: Age-dependent colocalization with vasopressin, Brain Res 1993;615:50-62.
31. Raadshccr FC, Hoogendijk WJG, Stam FC, Tilders FJH, Swaab DF: Increased numbers of corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus of depressed patients, Ncurocndocri-nology 1994:60:436-443.
32. Purba JS, Witte JG, Hoogendijk WJG, Hof-man MA, Swaab DF: Increased number of vasopressin and oxytocin expressing neurons in the paraventricular nucleus of the human hypothalamus in depression, Arch Gen Psychiatry 1996;53:137-143.
33. Trapp T, Rupprecht R, Castren M, Lombes M, Reul JMHM, Holsboer F: Heterodimerization between mineralocorticoid and glucocorticoid receptor: A new principle of glucocorticoid action in the central nervous system, Neuron 1994;13:1-6.
34. Truss M, Beato M: Steroid hormone receptor: Interaction with deoxyribonucleic acid and transcription factors, Endocr Rev 1993; 14: 460-479.
35. Holsboer F, Barden N: Ant ¡depressants and hypolhalamic-pituitary-adrenocortical regulation, Endocr Rev 1996;2:187-205.
36. Brady LS, Gold PW, Herkcnham M, Lynn AB, Whitfield HJ Jr: The antidepressants fluoxetine, idazoxan and phenelzine alter corticotropin-releasing hormone and tyrosine hydroxylase mRNA levels in the rat brain: Therapeutic implications, Brain Res 1992:572:117-125.
37. Reul JMHM, Stec I, Söder M, Holsboer F: Chronic treatment of rats with the antidcpressant amitriptyline attenuates the activity of the hypolhalamic-pituitary-adrenocortical system, Endocrinology 1993:133:312-320.
38. Reul JMHM, Labcur MS, Grigoriadis DE, De Souza EB, Holsboer F: Hypothalamic-pituitary-adrenocortical axis change in the rat after long-term treatment with the reversible monoamine oxidasc-A inhibitor moclobemidc, Neuroendocrinology 1994:60:509-519.
39. Richard D, Chapdelaine S, Deshaies Y, Pepin MC, Barden N: Energy balance and lipid metabolism in transgenic mice bearing an anti-sense glucocorticoid receptor gene construct, Am J Physiol 1993;265:R146-R150.
40. Monlkowski A, Barden N, Wotjak C, Stec I, Ganster J, Meaney M, Engelmann M, Reul JMHM, Landgraf R, Holsboer F: Long-term antidepressant treatment reduces behavioural deficits in transgenic mice with impaired glucocorticoid receptor function, J Neuroendocrinol 1995;7:841-845.
41. Holsboer F, Liebl R, Hofschuster E: Repeated dexamethasone suppression test during depressive illness: Normalization of test results compared with clinical improvement, J Affect Disord 1982;4:93-101.
42. Greden JF, Gardner R, King D, Grunhaus L, Carroll BJ, Kronfol Z: Dexamethasone suppression test in antidepressani treatment of melancholia: The process of normalization and test re-test reproducibility, Arch Gen Psychiatry 1983;40:493-500.
43. Ribeiro SCM, Tandon R, Grunhaus L, Greden JF: The DST as a predictor of outcome in depression: A meta-analysis, Am J Psychiatry 1993;150:1618-1629.
44. Barden N, Reul JMHM, Holsboer F: Do anti-depressants stabilize mood through actions on the hypothalamic-pituitary-adrcnocortical system? Trends Neurosci 1995;18:6-11.